About Us

Home » About Us » HISTORY

History

Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado’s two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia. The Company was incorporated in Delaware on June 28, 2006.

In January 2011, Coronado acquired the assets of Asphelia Pharmaceuticals, Inc. relating to TSO (Trichuris suis ova or CNDO-201), a novel immunotherapy being developed for the treatment of Crohn’s disease, ulcerative colitis, multiple sclerosis and several other autoimmune disorders. These assets include exclusive rights to TSO in North America, South America and Japan under a sublicense agreement with OvaMed GmbH (OvaMed). In March 2012, Coronado entered into a Collaboration Agreement with OvaMed and Dr. Falk Pharma GmbH, OvaMed's sublicensee in Europe for gastroenterology indications, for the development of TSO for Crohn's disease.

In November 2007, Coronado acquired from UCL Business PLC, an affiliate of University College London ("UCLB"), exclusive worldwide rights to develop and market CNDO-109, a novel biologic that primes natural killer (NK) cells without the need for cytokines (IL-2). CNDO-109 is in clinical development for the treatment of acute myeloid leukemia (AML), and has demonstrated preclinical activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer.